Rep. Rick W. Allen Unloads Abbott Laboratories (NYSE:ABT) Stock

Representative Rick W. Allen (Republican-Georgia) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on August 18th, the Representative disclosed that they had sold between $15,001 and $50,000 in Abbott Laboratories stock on July 14th. The trade occurred in the Representative’s “LIVTR” account.

Representative Rick W. Allen also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 7/14/2026.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 7/14/2026.
• Sold $15,001 – $50,000 in shares of Intuit (NASDAQ:INTU) on 6/10/2026.

Abbott Laboratories Trading Up 2.2%

Shares of NYSE ABT opened at $116.62 on Friday. The business has a 50 day simple moving average of $100.08 and a 200 day simple moving average of $100.05. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock has a market cap of $201.80 billion, a price-to-earnings ratio of 37.74, a PEG ratio of 2.21 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is presently 81.55%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. UBS Group decreased their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research report on Thursday, August 13th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $118.67.

Institutional Trading of Abbott Laboratories

Large investors have recently modified their holdings of the company. J. Stern & Co. LLP raised its holdings in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the period. Norges Bank acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $2,938,892,000. Bank of America Corp DE acquired a new stake in shares of Abbott Laboratories in the second quarter valued at about $1,603,607,000. Legal & General Group Plc bought a new position in shares of Abbott Laboratories in the second quarter worth about $1,082,524,000. Finally, Flossbach Von Storch SE acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth about $902,938,000. 75.18% of the stock is owned by institutional investors.

About Representative Allen

Rick Allen (Republican Party) is a member of the U.S. House, representing Georgia’s 12th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Allen (Republican Party) ran for re-election to the U.S. House to represent Georgia’s 12th Congressional District. He won in the general election on November 5, 2024.

Allen was born in Augusta, Georgia, in 1951. He attended Auburn University in Alabama, graduating in 1973 with a B.S. in building construction.

After earning his degree, Allen worked as an estimator, project administrator and assistant to the president with a construction firm in Augusta. In 1976, he founded his own construction business, R. W. Allen & Associates, Inc. The company operates in six states across the country. In 2008, Allen was presented with the Augusta Metro Chamber of Commerce’s Small Business Person of the Year award.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.